Clinical Trial: NCT04161248
Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma
Status:
ACTIVE NOT RECRUITINGPhase:
Early Phase 1| Lead Sponsor: | Canadian Cancer Trials Group |
| Information Provided By: | Canadian Cancer Trials Group |
| Last Update Posted: | 2026-06-24 |
Study Overview
Brief Summary
The purpose of this study is to find the highest dose of a new drug, in combination with standard drugs, which can be tolerated without causing very severe side effects. The study treatment is new agents in combination with R-GDP or an equivalent regimen.
Official Title
A Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma
Conditions
Lymphoma, B-Cell
Intervention / Treatment
- Drug: Venetoclax
- Drug: Rituximab Injection
- Drug: Rituximab SC
- Drug: Gemcitabine
- Drug: Dexamethasone
- Drug: Cisplatin
- Drug: Glofitamab
- Drug: Tafasitamab
Other Study ID Numbers
- LY18
- ML40080
- A17-190
- I-00208-20-06
Start Date (Actual)
2020-09-02
Primary Completion Date (Estimated)
2026-12-31
Study Completion Date (Estimated)
2026-12-31
Enrollment (Actual)
40
Study Type
Interventional
Phase
Early Phase 1
| Lead Sponsor: | Canadian Cancer Trials Group |
| Information Provided By: | Canadian Cancer Trials Group |
| Last Update Posted: | 2026-06-24 |
Study Overview
Brief Summary
The purpose of this study is to find the highest dose of a new drug, in combination with standard drugs, which can be tolerated without causing very severe side effects. The study treatment is new agents in combination with R-GDP or an equivalent regimen.
Official Title
A Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma
Conditions
Lymphoma, B-Cell
Intervention / Treatment
- Drug: Venetoclax
- Drug: Rituximab Injection
- Drug: Rituximab SC
- Drug: Gemcitabine
- Drug: Dexamethasone
- Drug: Cisplatin
- Drug: Glofitamab
- Drug: Tafasitamab
Other Study ID Numbers
- LY18
- ML40080
- A17-190
- I-00208-20-06
Start Date (Actual)
2020-09-02
Primary Completion Date (Estimated)
2026-12-31
Study Completion Date (Estimated)
2026-12-31
Enrollment (Actual)
40
Study Type
Interventional
Phase
Early Phase 1